Answers are grounded in this paper and cite their sources.
PURPOSE: To evaluate the ability of magnetic resonance (MR) imaging enhanced with AMI-25 to depict and characterize hepatic tumors. MATERIALS AND METHODS: Sixty-four patients (41 men and 23 women, aged 24-65 years [mean, 55 years]) underwent 1-T MR imaging: 22 had metastatic disease; 10, hepatocellular carcinoma; seven, hemangioma; three, focal nodular hyperplasia; three, gallbladder adenocarcinoma; two, lymphoma; one, adenoma; and 16, no tumor. Pre- and postcontrast images (alone and in combination) were analyzed by three independent radiologists. Receiver operating characteristic curves were constructed to compare tumor characterization. RESULTS: Signal intensity was decreased in all benign tumors but not in malignant tumors. The number of tumors depicted (nonenhanced images, 657 tumors; enhanced, 753; and combined, 760) was not statistically different. Receiver operating characteristic curves did not show improved characterization with AMI-25. CONCLUSION: AMI-25 does not improve depiction of hepatic tumors. Although characterization of hepatic tumors was not improved with AMI-25, uptake of AMI-25 seems specific for hepatic tumors at MR imaging.
No takes yet. Share an insight, caveat, or question.
Denys et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: